Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures
Authors:
- Neus FalgàsNFNeus Falgàs
- Agnès Pérez‐MillanAPAgnès Pérez‐Millan
- Roser Sala‐LlonchRSRoser Sala‐Llonch
- Anna AntonellAAAnna Antonell
- Mircea BalasaMBMircea Balasa
- Sergi Borrego‐ÉcijaSBSergi Borrego‐Écija
- Oscar Ramos‐CampoyOROscar Ramos‐Campoy
- Josep Maria AugéJAJosep Maria Augé
- Magdalena CastellvíMCMagdalena Castellví
- Adrià Tort‐MerinoATAdrià Tort‐Merino
- Jaume OlivesJOJaume Olives
Open Access
- 16 January 2020
- journal article
- research article
- Published by Wiley in Human Brain Mapping
- Vol. 41 (8) , 2004-2013
Abstract
Prior studies have described distinct patterns of brain gray matter and white matter alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to investigate the relationship between early‐onset AD (EOAD) and FTLD structural alterations and CSF biomarker levels. We included 138 subjects (64 EOAD, 26 FTLD, and 48 controls), all of them with a 3T MRI brain scan and CSF biomarkers available (the 42 amino acid‐long form of the amyloid‐beta protein [Aβ42], total‐tau protein [T‐tau], neurofilament light chain [NfL], neurogranin [Ng], and 14‐3‐3 levels). We used FreeSurfer and FSL to obtain cortical thickness (CTh) and fraction anisotropy (FA) maps. We studied group differences in CTh and FA and described the “AD signature” and “FTLD signature.” We tested multiple regression models to find which CSF‐biomarkers better explained each disease neuroimaging signature. CTh and FA maps corresponding to the AD and FTLD signatures were in accordance with previous literature. Multiple regression analyses showed that the biomarkers that better explained CTh values within the AD signature were Aβ and 14‐3‐3; whereas NfL and 14‐3‐3 levels explained CTh values within the FTLD signature. Similarly, NfL levels explained FA values in the FTLD signature. Ng levels were not predictive in any of the models. Biochemical markers contribute differently to structural (CTh and FA) changes typical of AD and FTLD.Keywords
Funding Information
- Forskningsrådet för hälsa, arbetsliv och välfärd (2018‐02532)
- Generalitat de Catalunya (SLT002/16/00408, SLT008/18/00061, SLT002/16/00329)
- European Research Council (681712)
- Hjärnfonden (FO2017‐0243)
This publication has 42 references indexed in Scilit:
- CSF neurogranin as a neuronal damage marker in CJD: a comparative study with ADJournal of Neurology, Neurosurgery & Psychiatry, 2019
- Clinical applicability of diagnostic biomarkers in early‐onset cognitive impairmentEuropean Journal of Neurology, 2019
- Biomarkers for Alzheimer's disease: current status and prospects for the futureJournal of Internal Medicine, 2018
- CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degenerationNeurology, 2017
- Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementiaNeuroImage: Clinical, 2017
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year reviewJournal of Neurology, Neurosurgery & Psychiatry, 2010
- CSF detection of the 14-3-3 protein in unselected patients with dementiaNeurology, 2001
- Measuring the thickness of the human cerebral cortex from magnetic resonance imagesProceedings of the National Academy of Sciences, 2000
- Cortical Surface-Based AnalysisNeuroImage, 1999